5 results on '"Akgün, Eyup"'
Search Results
2. MMG22 Potently Blocks Hyperalgesia in Cisplatin-treated Mice.
- Author
-
Cataldo, Giuseppe, Lunzer, Mary M., Akgün, Eyup, Wong, Henry L., Portoghese, Philip S., and Simone, Donald A.
- Subjects
- *
HYPERALGESIA , *NEURALGIA , *MICE , *NERVOUS system injuries , *EXPERIMENTAL arthritis , *PAIN management , *VISCERAL pain - Abstract
• The bivalent ligand MMG22 consists of a MOR agonist and mGluR5 antagonist. • MMG22 reduced mechanical hyperalgesia produced by cisplatin in mice. • MMG22 reduced hyperalgesia without tolerance. • MMG22 may produce antinociception through the formation of a MOR-mGluR5 heteromer. MMG22 is a bivalent ligand containing MOR agonist and mGluR5 antagonist pharmacophores connected by a 22-atom linker. Intrathecal (i.t.) administration of MMG22 to inflamed mice has been reported to produce fmol-range antinociception in the reversal of LPS-induced hyperalgesia. MMG22 reduced hyperalgesia in the spared nerve injury (SNI) model of neuropathic pain at 10 days after injury but not at 30 days after injury, perhaps related to the inflammation that occurs early after injury but subsequently subsides. The present study determined the efficacy of MMG22 in cisplatin-treated male mice in order to provide data relating to the efficacy of MMG22 in the treatment of neuropathic pain that is associated with inflammation. Groups of eight mice each received daily intraperitoneal (i.p.) injections of cisplatin for seven days to produce robust mechanical allodynia defined by the decrease in withdrawal threshold using an electronic von Frey applied to the plantar surface of the hind paw. Intrathecal administration of MMG22 potently reduced mechanical hyperalgesia (ED 50 0.04 fmol/mouse) without tolerance, whereas MMG10 was essentially inactive. Morphine was less potent than MMG22 by >5-orders of magnitude and displayed tolerance. Subcutaneous MMG22 was effective (ED 50 = 2.41 mg/kg) and devoid of chronic tolerance. We propose that MMG22 induces the formation of a MOR-mGluR5 heteromer through selective interaction with the upregulated NR2B subunit of activated NMDAR, in view of the 4600-fold reduction of i.t. MMG22 antinociception by the selective NR2B antagonist, Ro25-6981. A possible explanation for the substantially reduced potency for MMG22 in the SNI model is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids.
- Author
-
Speltz, Rebecca, Lunzer, Mary M., Shueb, Sarah S., Akgün, Eyup, Reed, Rachelle, Kalyuzhny, Alex, Portoghese, Philip S., and Simone, Donald A.
- Subjects
- *
DRUG side effects , *SCIATIC nerve injuries , *DORSAL root ganglia , *OPIOID receptors , *NERVES , *WOUNDS & injuries , *THERAPEUTIC use of narcotics , *ANALGESICS , *NEURALGIA , *ANIMAL experimentation , *CELL receptors , *RESEARCH funding , *LIGANDS (Biochemistry) , *HYPERALGESIA , *MICE , *NEUROTRANSMITTER receptors - Abstract
Abstract: Functional interactions between the mu opioid receptor (MOR) and the metabotropic glutamate receptor 5 (mGluR5) in pain and analgesia have been well established. MMG22 is a bivalent ligand containing MOR agonist (oxymorphamine) and mGluR5 antagonist (MPEP) pharmacophores tethered by a 22-atom linker. MMG22 has been shown to produce potent analgesia in several models of chronic inflammatory and neuropathic pain (NP). This study assessed the efficacy of systemic administration of MMG22 at reducing pain behavior in the spared nerve injury (SNI) model of NP in mice, as well as its side-effect profile and abuse potential. MMG22 reduced mechanical hyperalgesia and spontaneous ongoing pain after SNI, with greater potency early (10 days) as compared to late (30 days) after injury. Systemic administration of MMG22 did not induce place preference in naive animals, suggesting absence of abuse liability when compared to traditional opioids. MMG22 also lacked the central locomotor, respiratory, and anxiolytic side effects of its monomeric pharmacophores. Evaluation of mRNA expression showed the transcripts for both receptors were colocalized in cells in the dorsal horn of the lumbar spinal cord and dorsal root ganglia. Thus, MMG22 reduces hyperalgesia after injury in the SNI model of NP without the typical centrally mediated side effects associated with traditional opioids. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.
- Author
-
Cataldo, Giuseppe, Lunzer, Mary M., Olson, Julie K., Akgün, Eyup, Belcher, John D., Vercellotti, Gregory M., Portoghese, Philip S., and Simone, Donald A.
- Subjects
- *
SICKLE cell anemia , *NOCICEPTIVE pain , *LIGANDS (Biochemistry) , *LIPOPOLYSACCHARIDES , *HYPERALGESIA , *PAIN management , *THERAPEUTIC use of narcotics , *ANALGESICS , *ANIMAL experimentation , *BIOLOGICAL models , *MICE , *NARCOTICS , *SENSORY perception , *RESEARCH funding , *PHARMACODYNAMICS - Abstract
Sickle cell disease (SCD) is a chronic inflammatory disorder accompanied by chronic pain. In addition to ongoing pain and hyperalgesia, vaso-occlusive crises-induced pain can be chronic or episodic. Because analgesics typically used to treat pain are not very effective in SCD, opioids, including morphine, are a primary treatment for managing pain in SCD but are associated with many serious side effects, including constipation, tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel treatments for pain in SCD. In this study, we used the Townes transgenic mouse model of SCD to investigate the antinociceptive efficacy of the bivalent ligand, MCC22, and compared its effectiveness with morphine. MCC22 consists of a mu-opioid receptor agonist and a chemokine receptor-5 (CCR5) antagonist that are linked through a 22-atom spacer. Our results show that intraperitoneal administration of MCC22 produced exceptionally potent dose-dependent antihyperalgesia as compared to morphine, dramatically decreased evoked responses of nociceptive dorsal horn neurons, and decreased expression of proinflammatory cytokines in the spinal cord. Moreover, tolerance did not develop to its analgesic effects after repeated administration. In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice.
- Author
-
Peterson, Cristina D, Kitto, Kelley F, Akgün, Eyup, Lunzer, Mary M, Riedl, Maureen S, Vulchanova, Lucy, Wilcox, George L, Portoghese, Philip S, and Fairbanks, Carolyn A
- Subjects
- *
ANALGESICS , *ANIMALS , *CELL receptors , *HYPERALGESIA , *SPINAL injections , *LIGANDS (Biochemistry) , *MICE , *NARCOTIC antagonists , *NEURALGIA , *NEUROTRANSMITTER receptors , *PHARMACODYNAMICS - Abstract
The mu opioid receptor (MOR) and metabotropic glutamate receptor 5 (mGluR5) are well-established pharmacological targets in the management of chronic pain. Both receptors are expressed in the spinal cord. MMG22, a bivalent ligand containing 2 pharmacophores separated by 22 atoms, which simultaneously activates MOR and antagonizes mGluR5, has been shown to produce potent reversal of tactile hypersensitivity in rodent models of lipopolysaccharide (LPS)-and bone cancer-induced chronic pain. This study assessed whether intrathecal MMG22 also is effective in reducing pain of neuropathic origin. Furthermore, we theorized that MMG22 should reduce hyperalgesia in nerve-injured mice in a manner consistent with a synergistic interaction between MOR and mGluR5. Several weeks after spared nerve injury, tactile hypersensitivity was reversed in mice by the intrathecal injection of MMG22 (0.01-10 nmol) but also by its shorter spacer analog, MMG10, with similar potency. The potencies of the bivalent ligands were 10- to 14-fold higher than those of the compounds upon which the bivalent structure was based, the MOR agonist oxymorphone and the mGluR5 antagonist MPEP. Coadministration of oxymorphone and MPEP demonstrated analgesic synergism, an interaction confirmed by isobolographic analysis. This study indicates that in the spared nerve injury-induced model of neuropathic pain, the 2 pharmacophores of the bivalent ligands MMG22 and MMG10 target MOR and mGluR5 as separate receptor monomers. The observed increase in the potency of MMG22 and MMG10, compared with oxymorphone and MPEP, may reflect the synergistic interaction of the 2 pharmacophores of the bivalent ligand acting at their respective separate receptor monomers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.